Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) was downgraded by investment analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued to investors on Monday.

Several other research analysts also recently weighed in on the stock. Zacks Investment Research upgraded shares of Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, July 13th. Jefferies Group LLC restated a “buy” rating and set a $32.00 price target on shares of Zynerba Pharmaceuticals in a research report on Sunday, July 9th. Cantor Fitzgerald restated a “buy” rating and set a $28.00 price target on shares of Zynerba Pharmaceuticals in a research report on Tuesday, May 9th. BidaskClub upgraded shares of Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, July 12th. Finally, Maxim Group set a $32.00 price target on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, June 26th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company’s stock. Zynerba Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $29.11.

Shares of Zynerba Pharmaceuticals (NASDAQ:ZYNE) traded down 55.71% on Monday, hitting $6.67. The stock had a trading volume of 9,000,677 shares. The firm’s market cap is $88.42 million. Zynerba Pharmaceuticals has a 12 month low of $5.93 and a 12 month high of $25.95. The firm’s 50-day moving average price is $17.81 and its 200 day moving average price is $19.61.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last released its quarterly earnings results on Tuesday, August 1st. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.60) by $0.04. Analysts anticipate that Zynerba Pharmaceuticals will post ($2.46) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Zynerba Pharmaceuticals, Inc. (ZYNE) Downgraded to Strong Sell at ValuEngine” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2017/08/07/zynerba-pharmaceuticals-inc-zyne-downgraded-to-strong-sell-at-valuengine.html.

In other Zynerba Pharmaceuticals news, CFO James E. Fickenscher acquired 5,200 shares of the business’s stock in a transaction on Friday, May 12th. The stock was bought at an average price of $19.82 per share, for a total transaction of $103,064.00. Following the acquisition, the chief financial officer now owns 12,200 shares in the company, valued at $241,804. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Chairman Armando Anido acquired 5,000 shares of the business’s stock in a transaction on Monday, May 15th. The stock was acquired at an average price of $19.70 per share, with a total value of $98,500.00. Following the acquisition, the chairman now owns 336,012 shares in the company, valued at approximately $6,619,436.40. The disclosure for this purchase can be found here. 10.02% of the stock is currently owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the stock. Marshall Wace North America L.P. acquired a new stake in Zynerba Pharmaceuticals during the first quarter worth approximately $9,362,000. Vanguard Group Inc. boosted its stake in Zynerba Pharmaceuticals by 53.9% in the first quarter. Vanguard Group Inc. now owns 425,811 shares of the company’s stock valued at $8,559,000 after buying an additional 149,094 shares during the period. Pennsylvania Trust Co purchased a new stake in Zynerba Pharmaceuticals during the second quarter valued at $2,366,000. Sphera Funds Management LTD. purchased a new stake in Zynerba Pharmaceuticals during the first quarter valued at $2,010,000. Finally, Granite Point Capital Management L.P. purchased a new stake in Zynerba Pharmaceuticals during the first quarter valued at $1,990,000. Institutional investors own 31.08% of the company’s stock.

About Zynerba Pharmaceuticals

Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Receive News & Ratings for Zynerba Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.